Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

View ORCID ProfileChristine M. Lovly, Kelli L. Boyd, Paula I. Gonzalez-Ericsson, Cindy L. Lowe, Hunter M. Brown, Robert D. Hoffman, Brent C. Sterling, Meghan E. Kapp, Douglas B. Johnson, Prasad R. Kopparapu, Wade T. Iams, Melissa A. Warren, Michael J. Noto, Brian I. Rini, Madan Jagasia, Suman R. Das, Justin M. Balko
doi: https://doi.org/10.1101/2020.04.29.20085738
Christine M. Lovly
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christine M. Lovly
  • For correspondence: christine.lovly{at}vumc.org
Kelli L. Boyd
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
D.V.M., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula I. Gonzalez-Ericsson
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cindy L. Lowe
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hunter M. Brown
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert D. Hoffman
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brent C. Sterling
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meghan E. Kapp
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D., M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas B. Johnson
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D., M.S.C.I.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prasad R. Kopparapu
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wade T. Iams
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa A. Warren
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Noto
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian I. Rini
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madan Jagasia
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
M.B.B.S., M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suman R. Das
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin M. Balko
Departments of Medicine Pathology, Microbiology, and Immunology and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville; TN
Pharm.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Immune checkpoint inhibitors (ICIs) are used for the treatment of numerous cancers, but risks associated with ICI-therapy during the COVID-19 pandemic are poorly understood. We report a case of acute lung injury in a lung cancer patient initially treated for ICI-pneumonitis and later found to have concurrent SARS-CoV-2 infection. Post-mortem analyses revealed diffuse alveolar damage in both the acute and organizing phases, with a predominantly CD68+ inflammatory infiltrate. Serum was positive for anti-SARS-CoV-2 IgG, suggesting that viral infection predated administration of ICI-therapy and may have contributed to a more fulminant clinical presentation. These data suggest the need for routine SARS-CoV-2 testing in cancer patients, where clinical and radiographic evaluations may be non-specific.

Competing Interest Statement

C.M.L. is a consultant/advisory board member for Foundation Medicine, Pfizer, Novartis, AstraZeneca, Genoptix, Sequenom, Ariad, Takeda, Blueprints Medicine, Cepheid, Achilles, Genentech, Eli Lilly, and reports receiving commercial research grants from Xcovery and Novartis. D.B.J. is a consultant/advisory board member for Array Biopharma, BMS, Jansen, Merck, and Novartis, and receives research funding from BMS and Incyte. W.T.I. reports consulting for Genentech, Outcomes Insights, and Defined Health. J.M.B. receives research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation, and has received consulting/expert witness fees from Novartis. B.I.R. receives research funding from Merck, Roche, Pfizer, AVEO, Peloton, BMS, Astra-Zeneca, owns stock in PTC Therapeutics, and has done consulting for Merck, Roche, Pfizer, AVEO, Peloton, BMS, Arravive, 3D Medicines, Synthorx. M.J. is a consultant for Incyte, Kadmon, and Mallinckrodt. M.J.N received research funding from Gilead Sciences. No potential conflicts of interest were disclosed by the other authors.

Funding Statement

C.M.L. was supported by Lung Cancer Foundation of America / International Association for the Study of Lung Cancer Lori Monroe Scholarship, NCI R01CA227833, P30-CA086485, UG1CA233259, U54CA217450-01, U01CA224276-01, and P01CA129243-12. K.L.B. was supported by S10OD016355 and P30-CA086485. J.M.B and D.B.J were supported by NIH/NCI 1R01CA227481. W.T.I. was supported by NCI Vanderbilt Clinical Oncology Research Career Development Award (VCORCDP) 2K12CA090625-17.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of Interest: C.M.L. is a consultant/advisory board member for Foundation Medicine, Pfizer, Novartis, AstraZeneca, Genoptix, Sequenom, Ariad, Takeda, Blueprints Medicine, Cepheid, Achilles, Genentech, Eli Lilly, and reports receiving commercial research grants from Xcovery and Novartis. D.B.J. is a consultant/advisory board member for Array Biopharma, BMS, Jansen, Merck, and Novartis, and receives research funding from BMS and Incyte. W.T.I. reports consulting for Genentech, Outcomes Insights, and Defined Health. J.M.B. receives research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation, and has received consulting/expert witness fees from Novartis. B.I.R. receives research funding from Merck, Roche, Pfizer, AVEO, Peloton, BMS, Astra-Zeneca, owns stock in PTC Therapeutics, and has done consulting for Merck, Roche, Pfizer, AVEO, Peloton, BMS, Arravive, 3D Medicines, Synthorx. M.J. is a consultant for Incyte, Kadmon, and Mallinckrodt. M.J.N received research funding from Gilead Sciences. No potential conflicts of interest were disclosed by the other authors.

  • Funding: C.M.L. was supported by Lung Cancer Foundation of America / International Association for the Study of Lung Cancer Lori Monroe Scholarship, NCI R01CA227833, P30-CA086485, UG1CA233259, U54CA217450–01, U01CA224276–01, and P01CA129243–12. K.L.B. was supported by S10OD016355 and P30-CA086485. J.M.B and D.B.J were supported by NIH/NCI 1R01CA227481. W.T.I. was supported by NCI Vanderbilt Clinical Oncology Research Career Development Award (VCORCDP) 2K12CA090625–17.

Data Availability

Reviewed the CARE Checklist of information to include when writing a case report. For item #12 in the checklist “The patient should share their perspective in one to two paragraphs on the treatment(s) they received” -- our case report is about a deceased patient, so we were unable to obtain the patient’s perspective on the treatment received.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 01, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer
Christine M. Lovly, Kelli L. Boyd, Paula I. Gonzalez-Ericsson, Cindy L. Lowe, Hunter M. Brown, Robert D. Hoffman, Brent C. Sterling, Meghan E. Kapp, Douglas B. Johnson, Prasad R. Kopparapu, Wade T. Iams, Melissa A. Warren, Michael J. Noto, Brian I. Rini, Madan Jagasia, Suman R. Das, Justin M. Balko
medRxiv 2020.04.29.20085738; doi: https://doi.org/10.1101/2020.04.29.20085738
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer
Christine M. Lovly, Kelli L. Boyd, Paula I. Gonzalez-Ericsson, Cindy L. Lowe, Hunter M. Brown, Robert D. Hoffman, Brent C. Sterling, Meghan E. Kapp, Douglas B. Johnson, Prasad R. Kopparapu, Wade T. Iams, Melissa A. Warren, Michael J. Noto, Brian I. Rini, Madan Jagasia, Suman R. Das, Justin M. Balko
medRxiv 2020.04.29.20085738; doi: https://doi.org/10.1101/2020.04.29.20085738

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)